Ubiquinone coenzyme Q-10

Name: Ubiquinone coenzyme Q-10

What happens if I miss a dose?

Skip the missed dose if it is almost time for your next scheduled dose. Do not use extra medicine to make up the missed dose.

Ubiquinone side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Although not all side effects are known, ubiquinone is thought to be likely safe for most adults when used as directed.

Stop using ubiquinone and call your healthcare provider at once if you have:

  • very low blood pressure--dizziness, severe weakness, feeling like you might pass out.

Common side effects may include:

  • upset stomach, nausea, vomiting, loss of appetite;

  • diarrhea;

  • skin rash; or

  • low blood pressure.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect ubiquinone?

Do not take ubiquinone without medical advice if you are using any of the following medications:

  • omega-3 fatty acids;

  • vitamins (especially A, C, E, or K);

  • blood pressure medicine;

  • cancer medicine; or

  • warfarin (Coumadin, Jantoven).

This list is not complete. Other drugs may interact with ubiquinone, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this product guide.


Absolute contraindications have not been identified.


Findings are conflicting. Case reports show ubiquinone decreases the anticoagulant effect of warfarin; however, a randomized clinical trial found no effect on the international normalized ratio (INR).


An observed intake safety level of 1,200 mg/day is based on clinical data; however, dosages exceeding this amount have been used with no apparent adverse effect. No accumulation in plasma or tissue following cessation of coenzyme Q10 consumption has been noted.

Ubiquinones are a class of lipid-soluble benzoquinones that are involved in mitochondrial electron transport. They are found in the majority of aerobic organisms, from bacteria to mammals, hence the name ubiquinone (“ubiquitous quinone”).


The first ubiquinone was isolated in 1957. Since that time, ubiquinones have been studied extensively in Japan, Russia, and Europe, with research in the United States beginning more recently. Popular press accounts claim that roughly 12 million Japanese people use ubiquinones as the medication of choice for management of cardiovascular diseases, supplied via more than 250 commercially available preparations. Ubiquinone is touted as an effective treatment for CHF, cardiac arrhythmias, hypertension, and in reducing hypoxic injury to the myocardium. Other claims include increases in exercise tolerance, stimulation of the immune system, and counteraction of the aging process. Ubiquinone has not been approved for therapeutic use in the United States; however, it is available as a food supplement. 1

Uses and Pharmacology

Cardiovascular disease

The American College of Cardiology does not support the use of coenzyme Q10 in cardiovascular disease because a mortality benefit has not been established, 4 while the Agency for Healthcare Research and Quality finds no convincing evidence to either support or refute coenzyme Q10's place in therapy. 5

Animal data

The widespread use of coenzyme Q10 as a supplement and the availability of numerous trial data suggesting the relative nontoxicity of the compound makes data derived from animal experiments less important.

Clinical data
Cardiac surgery/Cardiac arrest

The use of coenzyme Q10 in improving mitochondrial function has been evaluated in cardiac surgery. A review was published of 8 studies, in which improvements in contractility of the myocardial tissue were demonstrated in association with increases in serum coenzyme Q10. 6 , 7 Doses of coenzyme Q10 300 mg daily for 2 weeks prior to surgery were evaluated versus placebo. 6 A randomized, placebo-controlled trial evaluated coenzyme Q10 450 mg in divided doses in conjunction with hypothermia after cardiac arrest. Increased survival was shown for the coenzyme Q10 group. 8

Congestive heart failure

Several meta-analyses and systematic reviews of clinical trials in CHF have been published, with results generally being more consistent for CHF than with other disease states. 4 , 7 , 9 , 10 , 11 , 12 , 13 , 14 The inclusion of 2 trials in which coenzyme Q10 failed to show an effect greater than placebo in these analyses, results in only a trend in favor of ubiquinone in improving cardiac function (an increase in resting ejection fraction of 1.9% [95% confidence interval [CI], −0.13% to 3.9%]). 4 , 7 , 9 , 12 In a meta-analysis that included trials with a crossover or parallel-arm design, a 3.7% absolute difference in resting ejection fraction was found for coenzyme Q10 (95% CI, 1.59 to 5.77). 7 , 11

The studies, however, either do not evaluate or are underpowered to evaluate mortality outcomes. 7 , 11 , 15 Because differing ubiquinone preparations were used in the studies, both the bioavailability of the compound 7 , 16 and the adequacy of dosing to reach sufficient plasma coenzyme Q10 levels for effect have been questioned. 13 , 14


Systematic reviews and meta-analyses have been conducted evaluating coenzyme Q10 in hypertension versus placebo. Trials comparing coenzyme Q10 with conventional therapy are lacking. 7 , 12 , 17 Decreases in systolic pressure were found in some patients. However, confounding variables, small trial size, and variable study designs make extrapolation of the data difficult. 7 , 12

Friedreich ataxia (hypertrophic cardiomyopathy)

Most studies used an open-label design. 7 , 18 Idebenone, an analog of coenzyme Q10, was commonly employed in these trials at dosages of 5 mg/kg/day to a maximum of 300 mg/day 19 and used for periods of 6 months to 5 years. 19 , 20 , 21 , 22 , 23 Increases in heart and skeletal muscle bioenergetics are reported for all the studies, as well as decreases in ventricular hypertrophy (left ventricular mass index). 19 , 20 , 21 , 22 , 23 Results for fractional shortening and ejection fraction are mixed, with 1 study reporting a deterioration 23 and another citing improvement in cardiac function. 22

Reversal of statin-induced myopathy

Statins (HMG-CoA reductase inhibitors) deplete circulating coenzyme Q10 levels by interfering with its biosynthesis. 7 , 10 , 24 Most studies indicate a correlation between the decrease in serum coenzyme Q10 and decreases of total and low-density lipoprotein cholesterol levels. This effect may be particularly important in elderly patients, in whom coenzyme Q10 levels are already compromised, and is also associated with higher dosages (lower dosages do not seem to affect intramuscular levels of coenzyme Q10). 24 , 25 The use of ezetimibe alone or in combination with a statin does not offer protection against depletion of coenzyme Q10. 10 , 24 No correlation has been established for decreased serum coenzyme Q10 and cardiovascular events. 7 , 24 Supplemental coenzyme Q10 increased circulating levels of the compound. However, results from randomized clinical trials are inconsistent in showing an effect on statin-associated myopathy. 3 , 16 , 24 , 26

Neurological disorders

The case for coenzyme Q10 as a treatment option in neurological (mitochondrial-related) disease is not as strong. 27 The role of coenzyme Q10 in Parkinson, Alzheimer, and Huntington diseases; amyotrophic lateral sclerosis; and Friedreich ataxia is postulated but not established. 2 , 28 , 29

Studies in Friedreich and non-Friedreich ataxia have largely shown a continued worsening of disease, as measured by the International Cooperative Ataxia Group rating scale, irrespective of idebenone use (5 mg/kg/day). 19 , 20 , 23 , 30 , 31

A link between mitochondrial dysfunction and Parkinson disease has been established, but the relationship with coenzyme Q10 has not. 32 A multicenter clinical trial found a decrease in worsening of symptoms in patients with early Parkinson disease receiving coenzyme Q10 1,200 mg/day, but not at lower dosages. 33 Effects were not apparent at 1 month, but were evident at 8 months. Changes in daily living factors were more pronounced than clinical disease progression changes. 32 , 34 Increases in plasma coenzyme Q10 were recorded. 33 A larger trial using higher dosages (coenzyme Q10 600 mg chewable wafers 4 times a day) found a mean change in total rating score high enough to warrant a phase 3 trial 35 ; however, the trial was not designed to evaluate efficacy. 34 , 35 A multicenter trial of patients receiving anti-Parkinson medication found no difference in symptoms over placebo. 36

The role of mitochondrial stress in Alzheimer disease led to more studies of coenzyme Q10. 31 Multicenter clinical trials using idebenone dosages of up to 360 mg 3 times a day found no effect on the rate of decline over placebo. Analyses using various rating scales showed some differences that were not considered clinically important, mirroring other older trials. 37 Similarly, no slowing of decline was noted in Huntington disease. 3

Other effects

Coenzyme Q10 has been evaluated in migraine versus placebo in small trials. Decreases in attack frequency, days with headache, and days with nausea were found for a daily dose of 300 mg. 38 The coadministration of ubiquinone with tamoxifen mitigated the hyperlipidemia associated with tamoxifen, and tumor marker levels indicated an antiangiogenesis effect. 39 An Agency for Healthcare Research and Quality review of clinical trials reported no evidence to support the use of ubiquinone in the prevention or treatment of cancer. 40

Deficiencies of coenzyme Q10 have been described, predominantly affecting children, in a spectrum of diseases including infantile-onset, multisystem diseases, as well as adult-onset cerebellar ataxia and pure myopathies. 28 , 29 Lymphocyte and platelet coenzyme Q10 levels were lower in Down syndrome, 41 while lowered serum levels are associated with phenylketonuria and mevalonic aciduria. 42

In infants with Prader-Willi syndrome, coenzyme Q10 had no effect on lean mass versus growth hormone. 43